Article

Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal protection against Omicron

2022-08-16

Abstract excerpt

To evaluate SARS-CoV-2 variants we isolated SARS-CoV-2 temporally during the pandemic starting with first appearance of virus in the Western hemisphere near Seattle, WA, USA, and isolated each known major variant class, revealing the dynamics of emergence and complete take-over of all new cases by current Omicron variants. We assessed virus neutralization in a first-ever full comparison across variants and evaluat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fb5ea99f-62aa-5e1f-9830-d6fe739eee5f
DOI: 10.1101/2022.08.12.22278720

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal protection against OmicronDOI 10.1101/2022.08.12.22278720Read

Mapping the antigenic diversification of SARS-CoV-2Semantic proximity Read

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartographySemantic proximity Read

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2Semantic proximity Read

Potent cross-reactive antibodies following Omicron breakthrough in vaccineesSemantic proximity Read

A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including OmicronSemantic proximity Read

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartographySemantic proximity Read

Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCsSemantic proximity Read

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read

SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasionSemantic proximity Read

Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron VariantSemantic proximity Read

Validation of neutralizing antibody titers for estimating vaccine effectiveness for the Omicron SARS-CoV-2 variant, BA.1Semantic proximity Read

SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesSemantic proximity Read